Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07156565 · ClinicalTrials.gov registry record · Phase 1
Actinium Therapy for Late-stage Aggressive Sarcomas
A Phase 1 study of Advanced Soft Tissue Sarcoma, sponsored by Ratio Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT07156565: Recruiting Phase 1 study of Advanced Soft Tissue Sarcoma, sponsored by Ratio Therapeutics.
NCT07156565 is a Phase 1 study of Advanced Soft Tissue Sarcoma that is actively recruiting participants, run by Ratio Therapeutics. The registered enrollment target is 30 participants, below the 86-participant average among 6 other Advanced Soft Tissue Sarcoma trials with a reported enrollment target (65% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07156565, a Phase 1 study of Advanced Soft Tissue Sarcoma, is actively recruiting participants, sponsored by Ratio Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma. The main questions the study aims to answer in Phase/Part 1 of the trial are: * Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients. * What is the most tolerable dose of \[Ac225\]RTX-2358 * Does the treatment show effectiveness on advanced sarcoma Participants will: * Take drug \[Ac225\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months * Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests. * For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests * Remain in long term follow-up for a period of four additional years
Primary Outcome
Frequency and severity of treatment emergent adverse events (TEAEs), Dose Limiting Toxicities (DLTs), serious adverse events (SAEs) and adverse events of special interest (AESIs).
Conditions Studied
Interventions
- DRUG [Ac 225]RTX-2358
- DIAGNOSTIC_TEST [Cu64]LNTH-1363S
Study Locations (6)
California
- UCLA - Los Angeles
Minnesota
- Mayo Clinic - Rochester
New York
- Memorial Sloane Kettering Cancer Center - New York
Ohio
- Case Western - Cleveland
Texas
- MD Anderson Cancer Center - Houston
Ontario
- Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2032-01 |
| Phase | Phase 1 |
What NCT07156565 shows while recruiting
NCT07156565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 86-participant average among 6 other Advanced Soft Tissue Sarcoma trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Advanced Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which [Ac 225]RTX-2358 is the first listed.
NCT07156565 lists 6 locations in 6 states (California, Minnesota, New York).
Frequently Asked Questions
What is clinical trial NCT07156565 about?
NCT07156565 is a clinical study titled "Actinium Therapy for Late-stage Aggressive Sarcomas". The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma. The main questions the study aims to answer in ...
What is the current status of trial NCT07156565?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-11-12. Estimated completion is 2032-01.
What conditions does trial NCT07156565 study?
This clinical trial studies the following conditions: Advanced Soft Tissue Sarcoma.
What interventions are being tested in trial NCT07156565?
The interventions under investigation include: [Ac 225]RTX-2358 (DRUG), [Cu64]LNTH-1363S (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07156565?
This trial is sponsored by Ratio Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07156565 being conducted?
This trial has 6 study locations across California, Minnesota, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Lurbinectedin + Doxorubicin In Leiomyosarcoma
ACTIVE NOT RECRUITING · Phase 1
-
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial
RECRUITING · Phase 2
-
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI